Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Antibody Structure01:10

Antibody Structure

61.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
61.4K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

359
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
359
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cu-Catalyzed Cross-Coupling of Cyclopropanol with Cyclobutanone Oximes To Access Distal Cyano Ketone.

Organic letters·2026
Same author

A General Photocatalytic Decarboxylative Hydrogenation of Carboxylic Acids in Batch and Flow under Metal-Free Conditions.

Organic letters·2026
Same author

Metal-free synthesis of highly substituted 2-aminopyridines by formal [3+3] annulation of α,α-dicyanoalkenes with imines.

Chemical communications (Cambridge, England)·2026
Same author

Nickel-Catalyzed 1,2-Distyrylation of 3-Buten-1-ol.

Organic letters·2026
Same author

Recent progress in catalytic asymmetric synthesis of triarylmethanes.

Chemical science·2026
Same author

Visible-Light-Promoted Carbamoylation: Access to Diarylhydrazine Carbonyl Amino Acid/Peptide Derivatives.

Organic letters·2026

Related Experiment Video

Updated: Sep 20, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Linker Design for the Antibody Drug Conjugates: A Comprehensive Review.

Yaxin Lei1,2, Minglei Zheng1,2, Peng Chen1

  • 1Henan Linker Technology Key Laboratory, College of Advanced Interdisciplinary Science and Technology, Henan University of Technology, NO. 100 Lianhua Street, Zhengzhou, 450001, China.

Chemmedchem
|May 28, 2025
PubMed
Summary

Antibody-drug conjugates (ADCs) offer targeted cancer therapy. Advances in linker technology are key to improving ADC efficacy and safety for next-generation treatments.

Keywords:
antibody–drug conjugatesbioconjugationsbranched linkersdrug release triggersspacers

More Related Videos

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.6K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K

Related Experiment Videos

Last Updated: Sep 20, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.6K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Bioconjugation Chemistry

Background:

  • Antibody-drug conjugates (ADCs) represent a targeted cancer therapy approach, combining monoclonal antibodies with cytotoxic payloads to overcome conventional chemotherapy limitations.
  • Seventeen ADCs are currently approved for treating hematologic and solid tumors, demonstrating clinical success but highlighting ongoing challenges in optimizing therapeutic potential.
  • The linker component is critical for ADC performance, influencing plasma stability and targeted payload release at the tumor site.

Purpose of the Study:

  • To provide an overview of clinically validated linker technologies in antibody-drug conjugates (ADCs).
  • To discuss recent innovations in ADC linker design, focusing on critical parameters for enhanced therapeutic outcomes.
  • To offer insights for the rational design of next-generation ADCs through an analysis of linker strategies and their effects.

Main Methods:

  • Review of clinically approved linkers and emerging linker technologies in antibody-drug conjugate (ADC) development.
  • Analysis of linker design elements including drug release triggers, bioconjugation strategies, spacer impact on hydrophilicity, traceless release, and overall architecture.
  • Discussion of the bystander effect in the context of ADC linker function.

Main Results:

  • Advances in linker technology over the past decade have significantly improved the pharmacokinetic, efficacy, and toxicity profiles of ADCs.
  • Specific linker design features, such as drug release mechanisms and spacer properties, directly impact ADC performance.
  • Understanding linker characteristics is essential for maximizing the therapeutic index of ADCs.

Conclusions:

  • Linker technology is a pivotal determinant of antibody-drug conjugate (ADC) success, complementing antibody and payload selection.
  • Innovations in linker design offer promising avenues for developing more effective and safer ADCs.
  • Further research into linker strategies, including the bystander effect, will guide the development of superior next-generation cancer therapies.